OpenEvidence, AC Forum Partner to Bring AI-Guided Antithrombotic Care to Clinicians

OpenEvidence and the Anticoagulation Forum (AC Forum) announced a strategic partnership on July 8 to expand access to artificial intelligence (AI)-enabled clinical guidance for antithrombotic care. The collaboration will integrate the AC Forum's evidence-based resources into OpenEvidence's clinical decision support platform, giving healthcare professionals access to specialty guidance within their existing workflows.

According to the announcement, the partnership combines the AC Forum's educational resources and multidisciplinary clinical guidance with OpenEvidence's AI-powered medical search platform to help clinicians make decisions on antithrombotic therapy. Antithrombotic medications are used to prevent or treat blood clots but require careful management because of the balance between reducing thrombosis risk and avoiding excessive bleeding.

AI platform expands specialty clinical guidance

Through the partnership, OpenEvidence users will gain access to the AC Forum's curated clinical resources, including concise guidance documents and practical decision-making tools designed for complex antithrombotic cases. The organizations also plan to identify common clinical questions and knowledge gaps using real-world platform usage, with those insights informing the development of additional educational resources.

"Clinicians are increasingly turning to AI to navigate the growing complexity of medical evidence," Travis Zack, MD, PhD, Chief Medical Officer at OpenEvidence, said. "Antithrombotic therapy touches nearly every area of medicine, and the Anticoagulation Forum has long been a trusted voice in this space. We are proud to partner with AC Forum to bring their expertise into everyday workflows, helping clinicians deliver safer, more effective care."

Geoff Barnes, MD, MSc, President of the AC Forum, said antithrombotic therapy remains one of medicine's highest-risk areas because clinicians must continuously balance clot prevention with bleeding risk.

"This partnership brings trusted, evidence-based guidance directly into clinical workflows through AI, helping clinicians make informed decisions with greater confidence, consistency, and efficiency," Barnes said.

The announcement builds on OpenEvidence's broader effort to embed specialty medical knowledge into its AI platform. Earlier this year, the company announced collaborations with organizations including the American College of Obstetricians and Gynecologists and publisher Wiley to expand physicians' access to trusted clinical content.

Healthcare AI moves deeper into clinical workflows

The partnership reflects a broader trend of healthcare AI vendors focusing on evidence retrieval and clinical decision support rather than administrative automation. OpenEvidence has increasingly positioned its platform as a point-of-care medical search engine that delivers source-cited answers grounded in peer-reviewed literature.

The company also continues to expand its presence across healthcare systems and physician organizations. On July 9, OpenEvidence announced a separate deployment with NewYork-Presbyterian, Columbia University, and Weill Cornell Medicine to expand access to its clinical AI tools across New York City and Westchester.

The latest partnership also follows OpenEvidence's rapid growth in the healthcare AI market after securing a $200 million funding round earlier this year that valued the company at $6 billion.

It also aligns with a broader movement to integrate AI-powered clinical evidence directly into physician workflows, including electronic health record environments, as health systems seek to reduce information retrieval time while maintaining evidence-based care.

The Anticoagulation Forum, which has members across more than 100 countries, said the collaboration is intended to advance antithrombotic stewardship by making evidence-based guidance more accessible during routine clinical decision-making.